Navigation Links
Aurobindo Receives Approval from USFDA for anti-AIDS drug

AIDS patients, the world over, can heave a sigh of relief following the nod of approval from the US Food & Drug Administration// (FDA) for the world’s first anti-AIDS cocktail drug for use as a single dose.

The drug manufacturer, Hyderabad-based bulk drugs major Aurobindo Pharma, has made combined anti-retro virals (ARVs) — Retrovir (zidovudine), Epivir (lamivudine) and Viramune (nevirapine) into a single three-in-one fixed dose drug.

The World Health Organisation (WHO) recognizes the three drugs as the first line of therapy for AIDS and they constitute about 50% of drug therapy against the disease.

Therefore the combination of the three drugs as a single tablet will result in fewer dosages as well as side-effects making life much easier for patients. Otherwise these patients have to consume about 20-30 pills a day for the Highly Active Antiretroviral Therapy (HAART) in treating AIDS.

With the US FDA approval means the drug can be sold immediately in over 15 countries as part of the $15 billion US President’s Emergency Plan for AIDS Relief (PEPFAR) programme.

Besides this, since the combination drug has now become a new drug it can receive new drug approval (NDA) and sold in the US markets, once the patents on the individual components expire. The combined market for these three drugs is estimated at a whopping $5 billion annually in the US alone.

The patents for these drugs in the US market expire in 2009 and 2010.

According to Lanka Srinivas, director, Aurobindo Pharma, 'This is indeed a major milestone for Aurobindo and, in fact, the whole country. What is further significant is that this is the first triple combination filing approved by the US FDA and, in fact, the first one ever filed.'

Lanka added that Aurobindo is targeting over $100 million in total revenues from the export of ARVs next year from the current $60 million.

'"/>




Page: 1

Related medicine news :

1. Aurobindo gets U.S. FDA approval for Cephalexin
2. US FDA approved Aurobindo Pharma to produce generic AIDS drug
3. Aurobindo Gets Tentative USFDA Approval For Its HIV-1 Drug
4. Aurobindo Pharma Purchases US Manufacturing Facility
5. Aurobindo Gets USFDA Approval for Didanosine Chewable Tablets
6. Aurobindo Gets USFDA Approval for A 3-Drug Combination Pack
7. Fifth US Patient Receives Artificial Heart
8. Northfield Labs Receives FDA Comments
9. British MPs Say Prostate Cancer Receives Low Priority in the NHS
10. Abbott Receives CE Mark Certification
11. Zactima Receives Fast Track Designation By The FDA
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs ... College of Mohs Surgery and to Dr. Russell Peckham for medical and surgical dermatology. ... treatment for skin cancer. The selective fellowship in Mohs Micrographic Surgery completed by Dr. ...
(Date:6/25/2016)... City, Oklahoma (PRWEB) , ... June 25, 2016 ... ... helping both athletes and non-athletes recover from injury. Recently, he has implemented orthobiologic ... the Oklahoma City area —Johnson is one of the first doctors to perform ...
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is World Sickle Cell Observance ... and the benefits of holistic treatments, Serenity Recovery Center of Marne, Michigan, ... Disease. , Sickle Cell Disease (SCD) is a disorder of the red blood cells, ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San Diego, ... and the Road To Recovery® program to drive cancer patients to and from their ... to ensure the highest quality of life and ongoing independence. Getting to and ...
(Date:6/24/2016)... Las Vegas, Nevada (PRWEB) , ... June 24, ... ... their Las Vegas client, The Grove Investment Group (TGIG), has initiated cultivation and ... The Grove, in Las Vegas and Pahrump, Nevada. , Puradigm is the manufacturer ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... Capricor Therapeutics, Inc. ... company focused on the discovery, development and commercialization ... in its ongoing randomized HOPE-Duchenne clinical trial (Halt ... its 24-patient target. Capricor expects the trial to ... 2016, and to report top line data from ...
(Date:6/23/2016)... 2016  Astellas today announced the establishment of Astellas Farma Colombia (AFC), a new affiliate with operations headquartered in ... America . ... ... ... ...
(Date:6/23/2016)... 2016  Experian Health, the healthcare industry ... patient payment and care experience, today announced ... and services that will enhance the breadth ... These award-winning solutions will enable healthcare professionals ... in an ever-changing environment and redefine front-office ...
Breaking Medicine Technology: